The FDA approved the norelgestromin and ethinyl estradiol transdermal system (Gwyn Lo, Viatris Inc), a once-weekly combined hormonal contraceptive patch, based on phase 3 data on efficacy, safety, and...
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approved gedatolisib with fulvestrant, with or without palbociclib, for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected after...
The FDA approved sacituzumab govitecan-hziy (Trodelvy) as monotherapy, and with pembrolizumab-based therapy, for select adults with previously untreated unresectable locally advanced or metastatic...
ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.
On May 22, 2026, the FDA approved datopotamab deruxtecan-dlnk for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy, based on...
In a phase 3 BWEL substudy, a lifestyle-based weight loss intervention improved patient-reported physical function, global health, social roles and activities, and fatigue in women with stage II-III breast...
The FDA approved Enhertu for neoadjuvant treatment of adults with HER2-positive stage II or III breast cancer and adjuvant treatment of patients with residual invasive disease after neoadjuvant therapy.
...
